Federal Register / Vol. 89, No. 243 / Wednesday, December 18, 2024 / Notices 102909 

3The data used by the Board are available on the 

BCBS website at https://www.bis.org/bcbs/gsib/ 

denominators.htm. 

4 12 CFR 217.404(b)(1)(i)(B); see also 80 FR 49082, 

49086–87 (August 14, 2015). In addition, the Board 

maintains the GSIB Framework Denominators on its 

website, available at https:// 

www.federalreserve.gov/supervisionreg/basel/ 

denominators.htm. 

5Foreign exchange rates provided by the BCBS. 

Available at https://www.bis.org/bcbs/gsib/ 

reporting_instructions.htm. 

under method 1 are based on data 

collected by the Basel Committee on 

Banking Supervision (BCBS). The BCBS 

amounts are determined based on the 

sum of the systemic indicator amounts 

as reported by the 75 largest U.S. and 

foreign banking organizations as 

measured by the BCBS, and any other 

banking organization that the BCBS 

includes in its sample total for that year. 

The BCBS publicly releases these 

amounts, denominated in euros, each 

year.3 Pursuant to the GSIB surcharge 

rule, the Board publishes the aggregate 

global indicator amounts each year as 

denominated in U.S. dollars using the 

euro-dollar exchange rate provided by 

the BCBS.4 Specifically, to determine 

the 2024 aggregate global indicator 

amounts, the Board uses the year-end 

2023 euro-denominated indicator 

amounts published by the BCBS and 

multiplies each of the eurodenominated indicator amounts by 

1.105, the euro to U.S. dollar spot 

exchange rate on December 31, 2023.5

The aggregate global indicator 

amounts expressed in U.S. dollars for 

purposes of the 2024 method 1 score 

calculation under § 217.404(b)(1)(i)(B) of 

the GSIB surcharge rule are: 

AGGREGATE GLOBAL INDICATOR AMOUNTS IN U.S. DOLLARS (USD) FOR 2024 

Category Systemic indicator 

Aggregate global 

indicator amount 

(in USD) 

Size ........................................................................ Total exposures ............................................................................... $115,205,051,188,518 

Interconnectedness ............................................... Intra-financial system assets ........................................................... 11,253,226,663,114 

Intra-financial system liabilities ........................................................ 11,388,383,441,235 

Securities outstanding ..................................................................... 19,247,590,871,111 

Substitutability ........................................................ Payments activity ............................................................................ 3,527,103,136,881,927 

Assets under custody ...................................................................... 219,479,268,261,988 

Underwritten transactions in debt and equity markets ................... 7,962,804,019,185 

Complexity ............................................................. Notional amount of over-the-counter (OTC) derivatives ................. 733,514,990,056,729 

Trading and available-for-sale (AFS) securities .............................. 4,278,831,961,372 

Level 3 assets ................................................................................. 803,127,442,989 

Cross-jurisdictional activity .................................... Cross-jurisdictional claims ............................................................... 28,416,427,492,687 

Cross-jurisdictional liabilities ........................................................... 23,524,643,383,930 

Authority: 12 U.S.C. 248(a), 321–338a, 

481–486, 1462a, 1467a, 1818, 1828, 

1831n, 1831o, 1831p–l, 1831w, 1835, 

1844(b), 1851, 3904, 3906–3909, 4808, 

5365, 5368, 5371. 

By order of the Board of Governors of the 

Federal Reserve System, acting through the 

Director of Supervision and Regulation under 

delegated authority. 

Ann E. Misback, 

Secretary of the Board. 

[FR Doc. 2024–29981 Filed 12–17–24; 8:45 am] 

BILLING CODE 6210–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

Notice of Meetings 

AGENCY: Agency for Healthcare Research 

and Quality (AHRQ), Department of 

Health and Human Services (HHS). 

ACTION: Notice of five AHRQ 

subcommittee meetings. 

SUMMARY: The subcommittees listed 

below are part of AHRQ’s Health 

Services Research Initial Review Group 

(IRG) Committee. Grant applications are 

to be reviewed and discussed at these 

meetings. Each subcommittee meeting 

will be closed to the public. 

DATES: See below for dates of meetings: 

1. Healthcare Safety and Quality 

Improvement Research (HSQR). 

Date: February 5–6, 2025. 

2. Healthcare Effectiveness and 

Outcomes Research (HEOR). 

Date: February 5–6, 2025. 

3. Health System and Value Research 

(HSVR). 

Date: February 13–14, 2025. 

4. Healthcare Research Training 

(HCRT). 

Date: February 27–28, 2025. 

5. Healthcare Information Technology 

Research (HITR). 

Date: February 27–28, 2025. 

ADDRESSES: Agency for Healthcare 

Research and Quality (Virtual Review), 

5600 Fishers Lane, Rockville, Maryland 

20857. 

FOR FURTHER INFORMATION CONTACT: (to 

obtain a roster of members, agenda or 

minutes of the non-confidential portions 

of the meetings.)Jenny Griffith, 

Committee Management Officer, 

Division of Policy, Coordination and 

Analysis, Office of Extramural Research 

Education and Priority Populations, 

Agency for Healthcare Research and 

Quality (AHRQ), 5600 Fishers Lane, 

Rockville, Maryland 20857, telephone 

(301) 427–1557. 

SUPPLEMENTARY INFORMATION: In 

accordance with the Federal Advisory 

Committee Act, 5 U.S.C. 1009(a)(2), 

AHRQ announces meetings of the 

above-listed scientific peer review 

groups, which are subcommittees of 

AHRQ’s Health Services Research Initial 

Review Group Committee. The 

subcommittee meetings will be closed to 

the public in accordance with the 

provisions set forth in 5 U.S.C. 1009(d), 

5 U.S.C. 552b(c)(4), and 5 U.S.C. 

552b(c)(6). The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Agenda items for these meetings are 

subject to change as priorities dictate. 

Dated: December 12, 2024. 

Marquita Cullom, 

Associate Director. 

[FR Doc. 2024–29969 Filed 12–17–24; 8:45 am] 

BILLING CODE 4160–90–P 


khammond on DSK9W7S144PROD with NOTICES